



US 20070027093A1

(19) **United States**

(12) **Patent Application Publication**  
**Ogawa et al.**

(10) **Pub. No.: US 2007/0027093 A1**  
(43) **Pub. Date: Feb. 1, 2007**

(54) **ANORECTIC**

**Publication Classification**

(75) Inventors: **Nobuya Ogawa**, Takatsuki (JP);  
**Chihiro Okuma**, Takatsuki (JP);  
**Noboru Furukawa**, Takatsuki (JP)

(51) **Int. Cl.**  
*A61K 31/70* (2007.01)  
*A61K 31/365* (2007.01)  
*A61K 31/542* (2007.01)  
*A61K 31/5383* (2007.01)  
*A61K 31/519* (2007.01)  
*A61K 31/426* (2007.01)  
*A61K 31/22* (2007.01)  
*A61K 31/175* (2006.01)  
(52) **U.S. Cl.** ..... **514/25**; 514/230.5; 514/260.1;  
514/224.2; 514/92; 514/423;  
514/460; 514/548; 514/369;  
514/635; 514/592

Correspondence Address:  
**LEYDIG VOIT & MAYER, LTD**  
**TWO PRUDENTIAL PLAZA, SUITE 4900**  
**180 NORTH STETSON AVENUE**  
**CHICAGO, IL 60601-6731 (US)**

(73) Assignee: **Japan Tobacco Inc.**, Tokyo (JP)

(21) Appl. No.: **11/495,095**

(22) Filed: **Jul. 28, 2006**

**Related U.S. Application Data**

(63) Continuation of application No. PCT/JP05/01643,  
filed on Jan. 28, 2005.

(60) Provisional application No. 60/598,037, filed on Aug.  
2, 2004.

(30) **Foreign Application Priority Data**

Jan. 30, 2004 (JP) ..... 2004-024812

(57) **ABSTRACT**

The present invention relates to an anorectic containing a compound having a DGAT inhibitory activity (DGAT1 inhibitory activity) or a prodrug thereof or a pharmaceutically acceptable salt thereof as an active ingredient. The present invention provides an anti-obesity drug which is an anorectic that does not directly act on the central nervous system and is satisfactory in terms of activity, and a therapeutic strategy for preventing or treating obesity.

## ANORECTIC

## TECHNICAL FIELD

[0001] The present invention relates to an anorectic action of a compound having a DGAT (diacylglycerol acyltransferase) inhibitory activity (e.g., DGAT1 inhibitory activity). Moreover, the present invention relates to a combined use of such DGAT inhibitors (e.g., DGAT1 inhibitor) and various drugs.

## BACKGROUND ART

[0002] It is known that various intracerebral neural activities and neurotransmitters are involved in the control of appetite in human and animals. These neural activities are affected by biochemical, neurological or endocrine signals that occur in the process of nutritive digestion, absorption, metabolism and storage.

[0003] Sugars and lipids themselves as nutrients, or metabolites in fat, muscle and liver cause biochemical signals that act promotively or suppressively on cerebral nerve activities involved in appetite.

[0004] It is also known that endocrine signals (e.g., CCK, GLP1, Enterostatin, ApoAIV etc.) or neural signals via chemical receptors of the gastrointestinal tract or from enteric plexus, during the process of digestion and absorption of sugars and lipids, affect gastrointestinal functions and cerebral nerve activities.

[0005] Moreover, it is known that fat tissue, which is a fat storage organ, produces endocrine or biochemical signals, such as leptin, adiponectin and free fatty acid, along with storage and consumption of fat. These signals alone or cooperative combinations of signals are considered to affect the central nervous system which controls appetite.


[0006] The DGAT1 inhibitor is expected to inhibit absorption of fat by suppressing re-synthesis of triglyceride in the gastrointestinal tract, and changes the above-mentioned signals that affect function of the gastrointestinal tract or brain.

[0007] In addition, the DGAT1 inhibitor is expected to change biochemical or endocrine signals from fat tissue by suppressing re-synthesis of triglyceride in the fat tissue.

[0008] Furthermore, it has been reported that DGAT1 deficient mice show an accelerated sensitivity of brain function to leptin which is an anti-obese factor derived from fat tissue. Therefore, a similar effect is expected by the administration of a DGAT1 inhibitor.


[0009] In the meantime, as a compound having a DGAT inhibitory activity, the following compounds are known.

[0010] The following compound has been disclosed to have a DGAT inhibitory activity (e.g., WO2004/17755).




[0011] This reference discloses inhibition of DGAT. However, disclosure of anorectic action resulting from the inhibition of DGAT as in the present application is not contained at all.

[0012] For example, the following compound has been disclosed to have a DGAT inhibitory activity (e.g., JP-A-H5-213985).




[0013] This reference discloses inhibition of ACAT and DGAT. However, disclosure of anorectic action resulting from the inhibition of DGAT as in the present application is not contained at all.

[0014] Similarly, the following compound has been disclosed to have a DGAT inhibitory activity (e.g., JP-A-H8-182496).




[0015] This reference discloses inhibition of DGAT. However, disclosure of anorectic action resulting from the inhibition of DGAT as in the present application is not contained at all.

[0016] Moreover, the following compound has been disclosed to have a DGAT inhibitory activity (e.g., WO00/




[0017] This reference discloses inhibition of DGAT. However, disclosure of anorectic action resulting from the inhibition of DGAT as in the present application is not contained at all.

[0018] Moreover, the following compound has been disclosed to have a DGAT inhibitory activity (e.g., JP-A-2004-67635).




[0019] This reference discloses inhibition of DGAT. However, disclosure of anorectic action resulting from the inhibition of DGAT as in the present application is not contained at all.

[0020] As a compound having an anorectic action, ApoB secretion/MTP (Microsomal Triglyceride Transfer Protein) inhibitors have been disclosed (e.g., JP-A-2001-181209). As such compound, for example, the following formula has been disclosed.



Specifically, the following compounds have been disclosed.



[0021] However, this reference does not disclose that these compounds have a DGAT inhibitory activity.

[0022] In addition, the reference discloses that similar compounds have been disclosed to have a suppressive action on fat absorption from small intestine, but does not disclose that these compounds have a DGAT inhibitory activity (e.g., JP-A-2001-172180).

[0023] While the development of anti-obesity drugs is currently ongoing, they are not satisfactory in terms of activity. The development of anorectic agents to prevent or treat obesity is also ongoing. However, since most of these anorectic agents directly act on the central nervous system and side effects are worried, the development of anorectic agents that do not directly act on the center has been strongly desired.

[0024] The problem to be solved by the present invention is provision of an anti-obesity drug which is an anorectic agent that does not directly act on the central nervous system and is satisfactory in terms of activity and a therapeutic


## DISCLOSURE OF THE INVENTION

[0025] In view of the above-mentioned problem, the present inventors have intensively studied in an attempt to search a useful anorectic and surprisingly found that a compound having a DGAT inhibitory activity (e.g., DGAT1 inhibitory activity) has a remarkable anorectic activity, which resulted in the completion of the present invention.

[0026] More particularly, the invention provides the following [1]-[33].

[1] An anorectic comprising, as an active ingredient, a compound having a DGAT (diacylglycerol acyltransferase) inhibitory activity or a prodrug thereof or a pharmaceutically acceptable salt thereof.

[0027] [2] The anorectic of the above-mentioned [1], wherein the compound having a DGAT inhibitory activity is a compound represented by the following formula (1):



wherein

[0028] X is C(R<sup>1</sup>) or N,

[0029] wherein R<sup>1</sup> is a hydrogen atom, a C<sub>1-8</sub> alkyl group, a C<sub>2-8</sub> alkenyl group, a C<sub>2-8</sub> alkynyl group, a C<sub>1-8</sub> fluoroalkyl group, an aryl group, an aryl C<sub>1-4</sub> alkyl group, C(O)R<sup>a</sup>, CO<sub>2</sub>R<sup>a</sup> or C(O)NR<sup>a</sup>R<sup>b</sup>, wherein R<sup>a</sup> and R<sup>b</sup> are the same or different and each is a hydrogen atom, a C<sub>1-8</sub> alkyl group, a C<sub>2-8</sub> alkenyl group, a C<sub>2-8</sub> alkynyl group, a C<sub>1-8</sub> fluoroalkyl group, an aryl group or an aryl C<sub>1-4</sub> alkyl group;

[0030] Y is C(R<sup>1</sup>), C(R<sup>2</sup>)(R<sup>2</sup>), N or N(R<sup>2</sup>),

[0031] wherein R<sup>1</sup> is as defined above and each R<sup>2</sup> is independently a hydrogen atom, a C<sub>1-8</sub> alkyl group, a C<sub>2-8</sub> alkenyl group, a C<sub>2-8</sub> alkynyl group, a C<sub>1-8</sub> fluoroalkyl group, C(O)R<sup>a</sup>, CO<sub>2</sub>R<sup>a</sup>, C(O)NR<sup>a</sup>R<sup>b</sup>, an aryl group or an aryl C<sub>1-4</sub> alkyl group, wherein R<sup>a</sup> and R<sup>b</sup> are as defined above;

[0032] Z is O or S;

[0033] W<sup>1</sup> is an optionally substituted C<sub>3-8</sub> cycloalkylene group, an optionally substituted C<sub>3-8</sub> heterocycloalkylene group, an optionally substituted arylene group or an optionally substituted heteroarylene group;

[0034] W<sup>2</sup> is an optionally substituted C<sub>3-8</sub> cycloalkyl group, an optionally substituted C<sub>3-8</sub> heterocycloalkyl group, an optionally substituted aryl group or an optionally substituted heteroaryl group;

[0035] L<sup>1</sup> is a single bond, a C<sub>1-4</sub> alkylene group, a C<sub>2-4</sub> alkenylene group, O, C(O)N(R<sup>a</sup>) or N(R<sup>a</sup>)C(O), wherein R<sup>a</sup> is as defined above;

[0036] L<sup>2</sup> is a single bond, O, a C<sub>1-4</sub> alkylene group, a C<sub>2-4</sub> alkenylene group, a C<sub>2-4</sub> alkynylene group, a C<sub>1-4</sub> fluoroalkylene group, an arylene group or an arylene group;

[0037] m is 0 or 1;

[0038] when m is 1 and L<sup>2</sup> is a single bond, a substituent of W<sup>2</sup> may form, together with a substituent of W<sup>1</sup>, a 5 to 7-membered ring that is condensed with W<sup>1</sup> and forms a fused ring or Spiro ring with W<sup>2</sup>;

[0039] R<sup>3</sup> and R<sup>4</sup>

[0040] are the same or different and each is a hydrogen atom, a C<sub>1-8</sub> alkyl group, a C<sub>2-8</sub> alkenyl group, a C<sub>2-8</sub> alkynyl group, C(O)R<sup>a</sup>, CO<sub>2</sub>R<sup>a</sup>, C(O)NR<sup>a</sup>R<sup>b</sup> or a C<sub>1-4</sub> alkylene-OR<sup>a</sup> group, wherein R<sup>a</sup> and R<sup>b</sup> are as defined above, or R<sup>3</sup> and R<sup>4</sup> may form a 3 to 6-membered ring together with the carbon atom binding thereto; or

[0041] R<sup>2</sup>, R<sup>3</sup> or R<sup>4</sup>

[0042] may form, together with W<sup>1</sup>, a 5 to 7-membered ring optionally having, in the ring, 1 to 3 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom;


[0043] R<sup>5</sup> and R<sup>6</sup>

[0044] are the same or different and each is a hydrogen atom, a C<sub>1-8</sub> alkyl group, a C<sub>2-8</sub> alkenyl group, a C<sub>2-8</sub> alkynyl group, C(O)R<sup>a</sup> or CO<sub>2</sub>R<sup>a</sup>, wherein R<sup>a</sup> is as defined above, R<sup>5</sup> and R<sup>6</sup> may form an N-containing 5 to 7-membered ring together with the nitrogen atom binding thereto, or, when X is C(R<sup>1</sup>), R<sup>5</sup> or R<sup>6</sup> may form, together with R<sup>1</sup>, an N-containing 5 to 7-membered ring, wherein N may be substituted by R<sup>5</sup> or R<sup>6</sup>;

[0045] R<sup>7</sup> is a hydrogen atom, a C<sub>1-8</sub> alkyl group, a C<sub>1-4</sub> haloalkyl group, a C<sub>2-8</sub> alkenyl group, a C<sub>2-8</sub> alkynyl group, C(O)R<sup>a</sup>, OR<sup>a</sup> or NR<sup>a</sup>R<sup>b</sup>, wherein R<sup>a</sup> and R<sup>b</sup> are as defined above, or, when X is C(R<sup>1</sup>), R<sup>7</sup> may form, together with R<sup>1</sup>, a 5 to 7-membered ring; and


..... is a single bond or a double bond;

provided that the following compound is excluded:



wherein R<sup>8</sup> is a hydrogen atom, a nitro group, a chlorine atom, a methoxy group, a methyl group or a phenyl group.

[3] The anorectic of the above-mentioned [1], wherein the compound having a DGAT inhibitory activity is a compound represented by the following formula (2):



wherein

[0046] X' and Y'


[0047] are the same or different and each is a single bond, a C<sub>1-4</sub> alkylene group, a C<sub>2-4</sub> heteroalkylene group, —O—, —CO<sub>2</sub>—, —S(O)<sub>k</sub>—,

[0048] —C(O)—, —NR<sup>7i</sup>—, —C(O)NR<sup>7i</sup>—, —N(R<sup>8i</sup>)C(O)NR<sup>7i</sup>—, —N(R<sup>7i</sup>)CO<sub>2</sub>—, —SO<sub>2</sub>NR<sup>7i</sup>—, —N(R<sup>8i</sup>)SO<sub>2</sub>NR<sup>7i</sup>—, —NR<sup>7i</sup>C(O)—, —O—C(O)N(R<sup>7i</sup>)— or —NR<sup>7i</sup>SO<sub>2</sub>—,

[0049] wherein R<sup>7i</sup> and R<sup>8i</sup> are the same or different and each is a hydrogen atom, a C<sub>1-8</sub> alkyl group, an aryl group or an aryl C<sub>1-4</sub> alkyl group and k is an integer of 0 or 1-2;

[0050] R<sup>1i</sup> is a hydrogen atom, a halogen atom, a C<sub>1-8</sub> alkyl group, a C<sub>2-8</sub> alkenyl group, a C<sub>2-8</sub> alkynyl group, a C<sub>1-8</sub> fluoroalkyl group, a C<sub>3-8</sub> cycloalkyl group, a C<sub>2-8</sub> heteroalkyl group, a C<sub>2-8</sub> heteroalkenyl group; a C<sub>3-8</sub> hetero-cycloalkyl group, an aryl group, an aryl C<sub>1-4</sub> alkyl group, a heteroaryl group, OR<sup>ai</sup>, SR<sup>ai</sup>, C(O)R<sup>ai</sup>, CO<sub>2</sub>R<sup>ai</sup>, C(O)NR<sup>ai</sup>R<sup>bi</sup>, SO<sub>2</sub>R<sup>ai</sup>, SO<sub>2</sub>NR<sup>ai</sup>R<sup>bi</sup> a nitro group or a cyano group, wherein R<sup>ai</sup> and R<sup>bi</sup> are the same or different and each is a hydrogen atom, a C<sub>1-8</sub> alkyl group, a C<sub>3-8</sub> cycloalkyl group, an aryl group or an aryl C<sub>1-4</sub> alkyl group;

[0051] R<sup>2i</sup> is a C<sub>1-8</sub> alkyl group, an aryl C<sub>1-4</sub> alkyl group, OR<sup>ai</sup>, a halogen atom, a nitro group, NR<sup>ai</sup>R<sup>bi</sup>, a cyano group or W<sup>1i</sup>, wherein W<sup>1i</sup> is




[0052] wherein R<sup>9</sup> and R<sup>10</sup> are the same or different and each is a hydrogen atom, a C<sub>1-8</sub> alkyl group, a C<sub>3-8</sub> cycloalkyl group, an aryl group or an aryl C<sub>1-4</sub> alkyl group;

group, an aryl group or an aryl C<sub>1-4</sub> alkyl group, or R<sup>9</sup> and R<sup>10</sup> may be linked to form a 5 to 7-membered ring optionally having, in the ring, 1 to 3 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, R<sup>11</sup> is a hydrogen atom, a C<sub>1-8</sub> alkyl group, an aryl group or an aryl C<sub>1-4</sub> alkyl group, and R<sup>ai</sup> and R<sup>bi</sup> are as defined above; or

[0053] R<sup>1i</sup> and R<sup>2i</sup>

[0054] may be linked to form a 5 to 7-membered ring optionally having, in the ring, one heteroatom selected from a nitrogen atom, an oxygen atom and a sulfur atom;

[0055] R<sup>3i</sup> is a hydrogen atom, a C<sub>1-8</sub> alkyl group, an aryl C<sub>1-4</sub> alkyl group, OR<sup>ai</sup>, a halogen atom, a nitro group, NR<sup>ai</sup>R<sup>bi</sup>, a cyano group or W<sup>2i</sup>, wherein W<sup>2i</sup> is



[0056] wherein R<sup>9</sup>, R<sup>10</sup> and R<sup>11</sup> are as defined above, and R<sup>ai</sup> and R<sup>bi</sup> are as defined above; or

[0057] R<sup>2i</sup> and R<sup>3i</sup>

[0058] may be linked to form a 5 to 7-membered ring optionally having, in the ring, one heteroatom selected from a nitrogen atom, an oxygen atom and a sulfur atom;

[0059] R<sup>4i</sup> is a C<sub>1-8</sub> alkyl group, a C<sub>2-8</sub> alkenyl group, a C<sub>3-8</sub> cycloalkyl group, an aryl group or an aryl C<sub>1-4</sub> alkyl group;

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.